No Pfizer ED drug ads till after the kids are asleep?; P&G plant cited for insanitary conditions;

> For the second time in four years, U.S. Rep. Jim Moran has introduced legislation that would ban erectile-dysfunction and male-performance-enhancement ads from commercial TV broadcasts between 6 a.m. and 10 p.m. Report

> FDA inspectors found that a Procter & Gamble plant in Puerto Rico was preparing, packing and holding OTC drug products under insanitary conditions and admonished the company for relying on preservatives to kill microogranisms in finished products, rather than prevent them from growing in the first place. Report 

> U.S. drugmaker Allergan has brought the curtain down on its manufacturing facility in Arklow, Ireland, months ahead of schedule. Report

> Genzyme said it will further expand its high-tech cell culture production facility in Geel, Belgium, with an investment of $61.6 million and 80 new jobs. Report

> It's official: Dr. Susan Desmond-Hellmann, former Genentech executive, was appointed chancellor of the University of California, San Francisco, campus by the University of California Board of Regents. Report

> Novartis is planning to build a new facility in Cambridge, MA, to further develop its partnership with the universities in the city. Report

> Endo Pharmaceuticals Holdings named Alan G. Levin executive vice president and chief financial officer to replace the position left open by Charles Rowland. Report

> The FBI is searching for hackers who demanded that Virginia pay them a $10 million ransom for the return of millions of personal pharmaceutical records stolen from the state's prescription drug database. Report

> Indian pharmaceutical companies are reworking their strategies for Europe to cope with the intense pressure on drug prices. Report

> Italy's Chiesi Farmaceutici will buy a 51 percent stake in Cornerstone Therapeutics, a respiratory drug developer, in a deal valued at $70 million. Report

> Canada's Paladin Labs has struck a deal on the development and commercialization of voclosporin, a next-generation calcineurin inhibitor that is Isotechnika's lead drug program. Voclosporin is being studied for psoriasis and transplants. Report

> After watching Vanda Pharmaceuticals' stock slide into the cellar in recent months, investors sent its shares into orbit after hearing that the FDA had approved its new drug for schizophrenia. Report

> Last year Archemix was in talks to merge with NitroMed, but that deal fizzled out. Now it appears that Archemix will have to make do with NitroMed's CEO. Report

> Vaccine experts at the World Health Organization plan to gather next week to consider whether the world's vaccine industry should start as early as May 14 to begin making mass quantities of a new swine flu vaccine. Report

> The Obama administration is considering whether the country should launch a fall vaccine campaign that administers three jabs, one for seasonal flu and two more to guard against swine flu. Report

And Finally... Americans aren't obese because they're couch potatoes, but because they eat too many potatoes (and too much of everything else, too). Report

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.